MedPath

Tagged News

Enveda Biosciences Raises $150M Series D to Advance AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Enveda Biosciences secured $150 million in Series D funding led by Premji Invest to advance its AI-powered drug discovery platform that mines natural molecules for therapeutic development.
  • The company has initiated Phase 1b testing of its lead candidate ENV-294 in atopic dermatitis, with the small molecule representing a completely new chemical class showing kinase inhibitor-like and steroid-like behavior.
  • Enveda's pipeline includes multiple programs targeting inflammatory bowel disease, fibrotic conditions, and obesity, with several investigational new drug applications planned for the coming year.
  • Former Pfizer Chief Scientific Officer Mikael Dolsten will join the company's board of directors as it aims to tackle large-market diseases driven by multiple mechanisms.

Syantra Launches Immuno-Oncology Therapeutic Division to Reverse Cancer-Related Immune Cell Corruption

Drug Discovery
  • Syantra, Inc. announced the formation of a new therapeutic division focused on developing first-in-class therapies to reverse cancer-related immune cell corruption and restore anti-cancer immunity.
  • The company's approach leverages its patent-pending Onco-ID™ platform to identify new drug targets that can reduce or reverse tumor "education" of immune cells.
  • Syantra secured additional funding from existing and new investors to support platform extensibility and commercialization efforts.
  • The technology may also be applied to patient selection and treatment monitoring to improve therapeutic outcomes.

Raina Biosciences Publishes Breakthrough AI Platform for mRNA Therapeutics in Science

AICAR-TDrug Discovery
  • Raina Biosciences announced publication of its GEMORNA platform data in Science, marking the world's first generative AI platform purpose-built for mRNA design and optimization.
  • GEMORNA-generated mRNAs demonstrated up to 150-fold increase in human erythropoietin expression and nearly 100% anti-tumor efficacy in primary human T cells compared to benchmarks.
  • The MIT spinout company closed a $5.7 million angel round and is collaborating with leading pharmaceutical and biotech companies to accelerate mRNA therapeutic development.
  • The platform addresses key limitations in mRNA therapeutics by designing sequences with enhanced expression levels and durability across diverse therapeutic applications.

Circurna Partners with GATC Health to Accelerate Circular RNA Therapeutics Using AI Platform

AIDrug Discovery
  • Circurna and GATC Health announced a strategic partnership to apply advanced AI technology for optimizing circular RNA therapeutics development.
  • The collaboration will leverage GATC's AI platform to enhance lipid nanoparticle designs, targeting ligands, and payload candidates for Circurna's ciRNA platform.
  • Circular RNA offers enhanced stability and protein expression compared to traditional mRNA, positioning it as a next-generation therapeutic modality.
  • GATC Health will receive cash, equity compensation, and milestone-based payments as part of the agreement terms.

Singapore's Nanyang Biologics Partners with Tech Giants to Accelerate AI-Powered Drug Discovery Platform

AIDrug Discovery
  • Nanyang Biologics has partnered with Equinix, Hewlett Packard Enterprise, and Nvidia to develop Vecura, an AI-enabled drug discovery platform that can identify potential drug candidates in as little as six minutes by 2026.
  • The platform builds on the company's earlier DTIGN technology, which successfully identified 15 potential drug candidates within six months for a Japanese pharmaceutical firm using graph neural networks and a library of compounds from over 50,000 organisms.
  • The global drug discovery platform market is projected to grow from $186 million in 2024 to $635 million by 2034, representing a compound annual growth rate of over 13 percent.
  • This collaboration positions Singapore as a leading hub for AI-enabled drug discovery, with Nanyang Biologics planning to commercialize the platform for other pharmaceutical companies while retaining intellectual property ownership.

Proxygen Partners with EPFL to Advance AI-Driven Molecular Glue Degrader Discovery

AIDrug Discovery
  • Proxygen, a leader in molecular glue degrader discovery, has announced a strategic research collaboration with EPFL to integrate AI-driven computational design with high-throughput screening platforms.
  • The partnership combines Proxygen's validated glue degrader discovery platform with Professor Bruno Correia's pioneering work in AI and structural modeling for protein design and therapeutic discovery.
  • The collaboration aims to systematically predict and validate neosubstrate-ligase interactions and design chemical matter capable of inducing targeted protein degradation across previously inaccessible target space.
  • This integrated approach is expected to accelerate glue degrader development with greater precision and scale, building on Proxygen's existing partnerships with major pharmaceutical companies including Merck KGaA and Merck & Co Inc.

SOHM Achieves Major Breakthrough with ABBIE Gene Editing Platform Using Advanced dCas12a Technology

Gene EditingDrug Discovery
  • SOHM successfully demonstrated that ABBIE version 2, featuring advanced dCas12a technology, can effectively modify cultured human cells, marking a critical advancement toward commercial-ready gene editing technology.
  • The breakthrough positions SOHM to pursue simultaneous multi-target editing capabilities through crRNA arrays, potentially offering unprecedented efficiency in gene modification applications.
  • The company successfully cloned an ovarian cancer cell line with confirmed GYS1 enzyme overexpression, demonstrating immediate commercial applications for drug screening and research partnerships.
  • The technological advancements significantly enhance SOHM's position for strategic partnerships and licensing opportunities in the global gene editing market, projected to reach $25 billion by 2030.

Tempus AI Acquires Paige to Build World's Largest Oncology Foundation Model

AIPrecision MedicineOncologyDrug Discovery
  • Tempus AI has acquired Paige, an AI company specializing in digital pathology with FDA-cleared cancer detection applications and nearly 7 million digitized pathology slides.
  • The $81.25 million stock acquisition positions Tempus to build the largest oncology foundation model in history by combining datasets and AI capabilities.
  • The strategic move strengthens Tempus' position in the digital pathology market projected to reach $10 billion by 2030, enhancing drug discovery and personalized medicine capabilities.
  • Paige's global dataset from 45 countries and partnership with Memorial Sloan Kettering Cancer Center adds significant credibility and diversity to Tempus' AI platform.

European Scientists Propose Alliance to Advance Proximity-Induced Drug Development for Undruggable Targets

Drug Discovery
  • Scientists from six leading European research institutions published a perspective in Molecular Cell proposing a European Alliance to accelerate development of proximity-induced drug modalities like PROTACs and molecular glue degraders.
  • These revolutionary therapeutics can remove entire disease-causing proteins by reprogramming cellular machinery, offering new possibilities for previously "undruggable" targets that conventional inhibitors cannot address.
  • The proposed alliance aims to pool expertise across European hubs in Frankfurt, Barcelona, Dundee, Lausanne, and Vienna to facilitate technology benchmarking, integrate computational approaches, and develop in vivo models.
  • The initiative builds on Germany's PROXIDRUGS Cluster4Future, which has secured €5 million annual funding since 2021 and seeks to expand internationally through academic-industry collaboration.

ChemPartner Establishes Boston R&D Center to Strengthen U.S. Biopharma Partnerships

Drug Discovery
  • ChemPartner, a global CRO and CDMO, will open a new 12,000 square foot R&D Center of Excellence in Watertown, Massachusetts on September 10, 2025.
  • The facility will provide biologics discovery, pharmacology, and DMPK services supporting both in vitro and in vivo studies from early discovery through IND-enabling stages.
  • The Boston expansion aims to address increasing complexity in biopharma partnerships, including bespoke service needs, tighter timelines, and evolving regulatory requirements.
  • The strategic location in the Boston biotech corridor enables enhanced collaboration with North American partners while improving logistics and coordination across regions.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.